PRESCRIPTION-ONLY products including cosmetic injections compounded by a pharmacy for an individual patient are still subject to the usual advertising regulations for Schedule 4 (S4) products, the Therapeutic Goods Administration (TGA) has clarified.
The TGA has issued a reminder to health professionals and cosmetic/beauty clinics which advertise cosmetic services that products containing S3, S4 and S8 ingredients all fall under the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) (the Poisons Standard).
Breaches of this regulation attract a maximum penalty of $10,800 for an individual and $54,000 for a body corporate, the TGA says.
Some cosmetic injections advertised to the public by health professionals and cosmetic/beauty clinics include hyaluronic acid, hyaluronan, sodium hyaluronate, collagen, botulinum toxin, polylactic acid, polyacrylamide, calcium hydroxyapatite, polycaprolactone or deoxycholic acid, all under different brand names.
These products are usually administered to temporarily remove or reduce wrinkles and lines on the face, around the eyes, forehead, lips and neck, or to improve the appearance of submental fat, and would all be subject to the Poisons Standard regulations, the TGA said.
To legally promote these businesses, the TGA has provided a list of acceptable general terms which if used without specific reference to individual S4 items, can still communicate the objectives of the therapy.
Visit tga.gov.au for details.
The above article was sent to subscribers in Pharmacy Daily's issue from 16 May 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 May 17
